BASF Pharma Ingredients and Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

20 years of making ibuprofen faster

Faster processes: Ibuprofen DC 85 helps to decrease production time and to reduce costs. Designed specifically for direct compression into tablets, Ibuprofen DC 85 offers a number of benefits compared to conventional formulations. A common challenge when processing ibuprofen is the relatively low melting point: the API gradually starts to melt during processing and can stick to the machinery – meaning production must be stopped to clean the tablet punches. The active ingredient in Ibuprofen DC 85, in contrast, is coated with a layer of nanomaterial, which provides protection during manufacturing. The result is reliable fault-free tableting production with higher output rates. Furthermore, as expensive wet granulation and compaction processing steps are no longer necessary, our customers can lower production costs.

Speed of action: Ibuprofen Sodium & Racemic Ibuprofen Lysinate (RIBL) dissolve faster than conventional ibuprofen. This means they provide more rapid and effective pain relief during the first hour – so patients are back to full speed in no time.

BASF, the world leader in generic APIs, has been deploying the industry’s most eco-efficient ibuprofen manufacturing process for over 20 years.

BASF Pharma Ingredients and Services
http://www.pharma-ingredients.basf.com/ibuprofen/Home.aspx
pharma-ingredients@basf.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here